Fatimat Kipkeeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fatimat Kipkeeva has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alexander V. Karpukhin
Research Centre for Medical Genetics
3 shared publications - Danzan Mansorunov
Research Centre for Medical Genetics, 1 Moskvorechye St., 115522 Moscow, Russia
3 shared publications - Maksim P. Nikulin
N.N. Blokhin National Medical Research Center of Oncology
3 shared publications - Olga A. Malikhova
Russian Medical Academy of Continuous Professional Education Ministry of Health of the Russian Federation
3 shared publications - Natalya V. Apanovich
Research Centre for Medical Genetics
2 shared publications - Pavel Apanovich
Research Centre for Medical Genetics, 1 Moskvorechye St., Moscow 115522, Russia
2 shared publications
Latest Publications
- Open Access
- 10 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 13846
The Correlation of Ten Immune Checkpoint Gene Expressions and Their Association with Gastric Cancer Development
In the immunotherapy based on immune checkpoint inhibition (IC), additional ICs are being studied to increase its effectiveness. An almost unstudied feature is the possible co-expression of ICs, which can determine the therapeutic efficacy of their inhibition. For the selection of promising ICs, information on the association of their expression with cancer development may be essential. We have obtained data on the expression correlation of ADAM17, PVR, TDO2, CD274, CD276, CEACAM1, IDO1, LGALS3, LGALS9, and HHLA2 genes in gastric cancer (GC). All but one, TDO2, have other IC genes with co-expression at some stage. At the metastatic stage, the expression of the IDO1 does not correlate with any other gene. The correlations are positive, but the expressions of the CD276 and CEACAM1 genes are negatively correlated. The expression of TDO2 and LGALS3 is associated with GC metastasis. The expression of TDO2 four-fold higher in metastatic tumors than in non-metastatic tumors, but LGALS3 was two-fold lower. The differentiation is associated with IDO1. The revealed features of TDO2, with a significant increase in expression at the metastatic stage and the absence of other IC genes with correlated expression indicates that the prospect of inhibiting TDO2 in metastatic GC. IDO1 may be considered for inhibition in low-differentiated tumors.
- 10 November 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 13846
Open AccessThe Correlation of Ten Immune Checkpoint Gene Expressions and Their Association with Gastric Cancer Development
In the immunotherapy based on immune checkpoint inhibition (IC), additional ICs are being studied to increase its effectiveness. An almost unstudied feature is the possible co-expression of ICs, which can determine the therapeutic efficacy of their inhibition. For the selection of promising ICs, information on the association of their expression with cancer development may be essential. We have obtained data on the expression correlation of ADAM17, PVR, TDO2, CD274, CD276, CEACAM1, IDO1, LGALS3, LGALS9, and HHLA2 genes in gastric cancer (GC). All but one, TDO2, have other IC genes with co-expression at some stage. At the metastatic stage, the expression of the IDO1 does not correlate with any other gene. The correlations are positive, but the expressions of the CD276 and CEACAM1 genes are negatively correlated. The expression of TDO2 and LGALS3 is associated with GC metastasis. The expression of TDO2 four-fold higher in metastatic tumors than in non-metastatic tumors, but LGALS3 was two-fold lower. The differentiation is associated with IDO1. The revealed features of TDO2, with a significant increase in expression at the metastatic stage and the absence of other IC genes with correlated expression indicates that the prospect of inhibiting TDO2 in metastatic GC. IDO1 may be considered for inhibition in low-differentiated tumors.
- Open Access
- 18 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (16) , 9324
The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer
Currently, the search for new promising tools of immunotherapy continues. In this regard, microRNAs (miRNAs) that influence immune checkpoint (IC) gene expression in tumor and T-cells and may be important regulators of immune cells are considered. MiRNAs regulate gene expression by blocking mRNA translation. An important feature of miRNA is its ability to affect the expression of several genes simultaneously, which corresponds to the trend toward the use of combination therapy. The article provides a list of miRNAs acting simultaneously on several ICs and miRNAs that, in addition to IC, can regulate the expression of targeted therapy genes. There is dependence of miRNA interactions with IC genes on the type of cancer. The analysis of the accumulated data demonstrates that only about 14% (95% CI: 9.8–20.1%) of the studied miRNAs regulate the expression of specific IC in more than one type of cancer. That is, there is tumor specificity in the miRNA action on ICs. A number of miRNAs demonstrated high efficiency in vitro and in vivo. This indicates the potential of miRNAs as promising agents for cancer immunotherapy. Additional studies of the miRNA–gene interaction features and the search for an optimal miRNA mimic structure are necessary.
- 18 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (16) , 9324
Open AccessThe Features of Immune Checkpoint Gene Regulation by microRNA in Cancer
Currently, the search for new promising tools of immunotherapy continues. In this regard, microRNAs (miRNAs) that influence immune checkpoint (IC) gene expression in tumor and T-cells and may be important regulators of immune cells are considered. MiRNAs regulate gene expression by blocking mRNA translation. An important feature of miRNA is its ability to affect the expression of several genes simultaneously, which corresponds to the trend toward the use of combination therapy. The article provides a list of miRNAs acting simultaneously on several ICs and miRNAs that, in addition to IC, can regulate the expression of targeted therapy genes. There is dependence of miRNA interactions with IC genes on the type of cancer. The analysis of the accumulated data demonstrates that only about 14% (95% CI: 9.8–20.1%) of the studied miRNAs regulate the expression of specific IC in more than one type of cancer. That is, there is tumor specificity in the miRNA action on ICs. A number of miRNAs demonstrated high efficiency in vitro and in vivo. This indicates the potential of miRNAs as promising agents for cancer immunotherapy. Additional studies of the miRNA–gene interaction features and the search for an optimal miRNA mimic structure are necessary.
- Open Access
- 16 December 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (12) , 2370
Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis
To increase the effectiveness of anticancer therapy based on immune checkpoint (IC) inhibition, some ICs are being investigated in addition to those used in clinic. We reviewed data on the relationship between PD-L1, B7-H3, B7-H4, IDO1, Galectin-3 and -9, CEACAM1, CD155, Siglec-15 and ADAM17 expression with cancer development in complex with the results of clinical trials on their inhibition. Increased expression of the most studied ICs—PD-L1, B7-H3, and B7-H4—is associated with poor survival; their inhibition is clinically significant. Expression of IDO1, CD155, and ADAM17 is also associated with poor survival, including gastric cancer (GC). The available data indicate that CD155 and ADAM17 are promising targets for immune therapy. However, the clinical trials of anti-IDO1 antibodies have been unsatisfactory. Expression of Galectin-3 and -9, CEACAM1 and Siglec-15 demonstrates a contradictory relationship with patient survival. The lack of satisfactory results of these IC inhibitor clinical trials additionally indicates the complex nature of their functioning. In conclusion, in many cases it is important to analyze the expression of other participants of the immune response besides target IC. The PD-L1, B7-H3, B7-H4, IDO1 and ADAM17 may be considered as candidates for prognosis markers for GC patient survival.
- 16 December 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (12) , 2370
Open AccessExpression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis
To increase the effectiveness of anticancer therapy based on immune checkpoint (IC) inhibition, some ICs are being investigated in addition to those used in clinic. We reviewed data on the relationship between PD-L1, B7-H3, B7-H4, IDO1, Galectin-3 and -9, CEACAM1, CD155, Siglec-15 and ADAM17 expression with cancer development in complex with the results of clinical trials on their inhibition. Increased expression of the most studied ICs—PD-L1, B7-H3, and B7-H4—is associated with poor survival; their inhibition is clinically significant. Expression of IDO1, CD155, and ADAM17 is also associated with poor survival, including gastric cancer (GC). The available data indicate that CD155 and ADAM17 are promising targets for immune therapy. However, the clinical trials of anti-IDO1 antibodies have been unsatisfactory. Expression of Galectin-3 and -9, CEACAM1 and Siglec-15 demonstrates a contradictory relationship with patient survival. The lack of satisfactory results of these IC inhibitor clinical trials additionally indicates the complex nature of their functioning. In conclusion, in many cases it is important to analyze the expression of other participants of the immune response besides target IC. The PD-L1, B7-H3, B7-H4, IDO1 and ADAM17 may be considered as candidates for prognosis markers for GC patient survival.
- Open Access
- 30 December 2017
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 16 (4) , 25-28
Expression profiles of potential target genes in disseminated gastric cancer
Objective is the investigation of messenger RNA quantitative expression profiles of potential target genes among disseminated gastric cancer cases. Materials and methods. Quantitative real-time polymerase chain reaction on paired tumor-normal samples. Results. The most frequently (25-41 % of cases) an increased level of messenger RNA in the tumor with respect to normal tissue was observed for the genes of TGF-ß (transforming growth factor ß), NRP-1 (neuropiline 1) and VEGF (vascular endothelial growth factor) family genes. For the first time a correlation between the expression levels of the three genes: NRP-1, TGF-ß and VEGFR-2, and the inverse correlation of the levels of VEGF and bFGF gene expression were found. Conclusion. The revealed correlation between the expression of TGF-ß, NRP-1 and VEGFR-2 genes is apparently due to the interaction of NRP-1 with the products of two other genes and may be associated with a high metastatic potential of the progressing tumor in disseminated gastric cancer. The observed inverse correlation of the VEGF-A and bFGF gene expression may indicate the stimulation of angiogenesis in the tumor with reduced activity of the VEGF pathway by activating the bFGF signaling pathway. The results obtained should be taken into account under targeted therapy.
- 30 December 2017
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 16 (4) , 25-28
Open AccessExpression profiles of potential target genes in disseminated gastric cancer
Objective is the investigation of messenger RNA quantitative expression profiles of potential target genes among disseminated gastric cancer cases. Materials and methods. Quantitative real-time polymerase chain reaction on paired tumor-normal samples. Results. The most frequently (25-41 % of cases) an increased level of messenger RNA in the tumor with respect to normal tissue was observed for the genes of TGF-ß (transforming growth factor ß), NRP-1 (neuropiline 1) and VEGF (vascular endothelial growth factor) family genes. For the first time a correlation between the expression levels of the three genes: NRP-1, TGF-ß and VEGFR-2, and the inverse correlation of the levels of VEGF and bFGF gene expression were found. Conclusion. The revealed correlation between the expression of TGF-ß, NRP-1 and VEGFR-2 genes is apparently due to the interaction of NRP-1 with the products of two other genes and may be associated with a high metastatic potential of the progressing tumor in disseminated gastric cancer. The observed inverse correlation of the VEGF-A and bFGF gene expression may indicate the stimulation of angiogenesis in the tumor with reduced activity of the VEGF pathway by activating the bFGF signaling pathway. The results obtained should be taken into account under targeted therapy.